MENU

Matthew R. Zibelman, MD

Matthew Zibelman, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Assistant Professor, Department of Hematology/Oncology

Kidney, Bladder, and Prostate Cancer TRDG Member

Treatment Philosophy

I am a medical oncologist specializing in the treatment of genitourinary cancers.  As a medical oncologist, I work with patients at all phases of malignant disease, which allows me the opportunity to join patients and families on a journey that can be at times both exhilarating and exhausting.  I understand that the patient-oncologist relationship is a unique partnership and one that I take seriously.  The journey of cancer provides access to moments in life that can be emotionally challenging for all parties, and I view my role as one ultimately about providing information and guidance to help navigate the path in the way best suited to each patient.

I find genitourinary oncology to be a particularly satisfying and exciting field within medical oncology.  It includes a diverse group of patients and a variety of different disease with their own unique opportunities and challenges.  It is an area involved in a great deal of research, which has afforded new treatment options for patients, and allows me to be involved in helping patients live longer, live better, and in some instances, even help cure them of their disease.    

Fortunately, at Fox Chase Cancer Center, our faculty and staff are dedicated and united towards one goal – optimally treating patients with cancer.  I completed my oncology training at Fox Chase and was fortunate to be able to continue as an attending physician at this world-class institution.  As part of Fox Chase, our patients have access to the cutting edge of clinical oncology, including the ability to have access to exciting new drugs as part of clinical trials.  Medical oncology is a rapidly evolving world, with new treatments and possibilities continually being made available to improve patient outcomes, and Fox Chase strives to remain at the forefront of those changes. 

Education and Training

Educational Background

  • Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Resident, Internal Medicine, University of Illinois at Chicago Medical Center, Chicago, IL
  • MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA

Memberships

  • Society for Immunotherapy of Cancer
  • American Society of Clinical Oncology
  • American Society of Hematology
Patient Stories

Davind Heinaman

Bladder Cancer;  Leukemia

Davind Heinaman

Bladder Cancer;  Leukemia

"Until September 2012 I thought statistics were just that; a tool. Then I learned I had a rare form of bladder cancer that accounts for less than one percent of all bladder cancers. I soon learned that bladder cancer itself comprises less than five percent of all cancers. After a bit of Internet searching I decided not to delve any deeper into the probabilities."

John Mullarkey, Jr.

Prostate Cancer

John Mullarkey, Jr.

Prostate Cancer

I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.

Research Profile

Research Interests

  • Genitourinary Oncology
  • Melanoma
  • Immunotherapy
Publications

Selected Publications

Zibelman M, Mehra R. Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell cancer of the head and neck. Am J Clin Oncol. Mar 2016. PubMed

Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology. 2016 Feb; 30(2): 160-2. PubMed

Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016 Feb 16;4:8. PubMed

Zibelman M, Wong YN, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.  Investigational New Drugs. June 20, 2015. PubMed

Zibelman M, Wong YN, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.  Investigational New Drugs. 2015 Oct; 33 (5): 1040-7.  PubMed

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM . A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report from the ClinicalTrials.gov Website. Clinical Genitourinary Cancer. 2015 Apr; 13(2):142-9. PubMed

Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune Checkpoint Blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discovery Medicine.  2014 Dec; 18 (101):341-50. PubMed

Zibelman M, Xiang Q, Muchka S, Nickoloff S, Marks S. Assessing Prognostic Documentation and Accuracy Amongst Palliative Care Clinicians. Journal of Palliative Medicine. 2014, May; 17(5) 521-26. PubMed

Zibelman M, Olszanski A. Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network.  Vol. 12, supp.  Sept 2014. JNCCN

Additional Publications

MyNCBI

Connect with Fox Chase